[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[S. 2814 Introduced in Senate (IS)]

<DOC>






117th CONGRESS
  1st Session
                                S. 2814

      To provide for affordable access to insulin and epinephrine.


_______________________________________________________________________


                   IN THE SENATE OF THE UNITED STATES

                           September 23, 2021

  Mr. Kennedy introduced the following bill; which was read twice and 
  referred to the Committee on Health, Education, Labor, and Pensions

_______________________________________________________________________

                                 A BILL


 
      To provide for affordable access to insulin and epinephrine.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Vital Medication Affordability 
Act''.

SEC. 2. ACCESS TO AFFORDABLE LIFE-SAVING DRUGS.

    Section 330(k)(3) of the Public Health Service Act (42 U.S.C. 
254b(k)(3)) is amended--
            (1) in subparagraph (M), by striking ``; and'' and 
        inserting a semicolon;
            (2) by redesignating subparagraph (N) as subparagraph (O); 
        and
            (3) by inserting after subparagraph (M) the following:
                    ``(N) in the case of a center that participates in 
                the drug discount program under section 340B, the 
                center has established, written practices to make 
                insulin and injectable epinephrine available at or 
                below the discounted price paid by the center or 
                subgrantee of the center under the drug discount 
                program under section 340B (plus a minimal 
                administration fee) to patients whose household income 
                in equal to or less than 350 percent of the Federal 
                poverty line and who--
                            ``(i) have a cost-sharing requirement under 
                        a health insurance plan for insulin or 
                        injectable epinephrine under which the patient 
                        out-of-pocket share is more than 20 percent of 
                        the total amount charged by the center for such 
                        insulin or epinephrine;
                            ``(ii) have a high unmet deductible under a 
                        health insurance plan; or
                            ``(iii) have no health insurance; and''.
                                 <all>